Skip to main content
PMC home page
Frontiers in Physiology logoLink to Frontiers in Physiology
. 2018 Jul 9;9:873. doi: 10.3389/fphys.2018.00873

Stanniocalcin 2 Ameliorates Hepatosteatosis Through Activation of STAT3 Signaling

Jiejie Zhao 1,2,†, Yang Jiao 1,2,†, Yuping Song 3,†, Jianmin Liu 1, Xiaoying Li 1,2, Huijie Zhang 4,*, Jialin Yang 3,*, Yan Lu 1,2,*
PMCID: PMC6046442  PMID: 30038584

Abstract

Stanniocalcin 2 (STC2), a secreted glycoprotein hormone, regulates many biological processes, including cell proliferation, apoptosis, tumorigenesis, and atherosclerosis. However, its role in hepatic triglyceride metabolism remains unknown. In the present study, we found that expression levels of STC2 were significantly reduced in the livers of leptin-deficient and high fat diet-induced obese mice. Systemic administration of STC2 recombinant protein or adenovirus-mediated overexpression of STC2 markedly attenuated hepatosteatosis and hypertriglyceridemia in obese mice. At the molecular level, we found that STC2 activated the STAT3 signaling pathway to inhibit lipogenic gene expression. Consistently, in vitro studies further showed that inhibition of STAT3 signaling abolished the anti-steatotic effects of STC2. Together, our results revealed an important role of STC2 in the regulation of hepatic triglyceride metabolism, which might provide a potential therapeutic target for the treatment of fatty liver and related metabolic disorders.

Keywords: stanniocalcin 2, STAT3, non-alcoholic fatty liver disease, triglyceride metabolism, lipogenesis

Introduction

Non-alcoholic fatty liver disease (NAFLD), defined as excess accumulation of triglycerides (TGs) in hepatocytes, has become the most common chronic liver condition and is estimated to impact at least 30% of Americans or Chinese (Browning et al., 2004; Williams et al., 2011; Wong et al., 2012). NAFLD can trigger a progressive cascade of liver disorders, ranging from hepatosteatosis to non-alcoholic steatohepatitis, liver cirrhosis, and even hepatocellular carcinoma (Farrell and Larter, 2006). Moreover, NAFLD is tightly associated with the development of type 2 diabetes, hypertension, atherosclerosis, and coronary heart disease (Marignani and Angeletti, 2002; Cohen et al., 2011).

Hepatosteatosis occurs when TG homeostasis is disrupted, due to increased TG synthesis and/or decreased TG clearance. In obesity-associated NAFLD, de novo lipogenesis (DNL) is increased, at least in part, by hyperinsulinemia as well as excess availability of carbohydrates (Lambert et al., 2014). Hepatic lipogenesis is mainly regulated by the transcription factor sterol regulatory element binding transcription protein 1c (SREBP-1c), which transcriptionally activates the expression of genes involved in DNL, including fatty acid synthetase (FASN), acetyl-CoA carboxylase (ACC1), and stearoyl-CoA desaturase-1 (SCD1). Indeed, increased hepatic expression levels of SREBP-1c and its target genes have been observed in obese rodents and humans (Shimomura et al., 1999; Horton et al., 2002).

Stanniocalcins (STC1 and STC2) were initially identified in bony fish as a calcium/phosphate-regulating hormone produced by the corpuscles of Stannius (Wagner et al., 1986). STC2 has the full-length of stanniocalcin sequence, while STC1 lacks a cysteine residue corresponding to Cys120 of STC2. Subsequent studies revealed that STC2 is ubiquitously expressed and acts as an endocrine, paracrine, or autocrine factor to regulate many biological processes, including tissue remodeling, cell survival, and stress responses (Law and Wong, 2010; Jepsen et al., 2016; Wu et al., 2017). Recently, increasing evidence highlighted its potential role in tumorigenesis, because its expression was markedly upregulated in several types of human malignancy, including stomach, colon, renal, and liver cancers (Meyer et al., 2009; Arigami et al., 2013; Chen et al., 2016; Wu et al., 2017). However, the role of STC2 in the regulation of hepatic TG homeostasis and in the pathogenesis of NAFLD remains unknown.

In the present study, we found that STC2 expression was reduced in the livers of leptin-deficient and high fat diet (HFD) -induced obese mice. Overexpression of STC2 significantly attenuated fatty liver and hypertriglyceridemia in obese mice through activation of the STAT3 signaling pathway. These findings revealed a vital role of STC2 in the regulation of hepatic TG homeostasis and suggested a promising therapeutic target for the related diseases.

Materials and Methods

Animal Experiments

Male C57BL/6 mice aged 8 weeks were purchased from the Shanghai Laboratory Animal Company (Shanghai, China). ob/ob mice were purchased from Nanjing Biomedical Research Institute of Nanjing University (Nanjing, Jiangsu Province, China). HFD-induced obese mice were maintained with free access to HFD (D12492; Research Diet, New Brunswick, NJ, United States) for 12 weeks, and control mice were fed with normal chow diet (NCD) (D12450B; Research Diet). STC2 recombinant protein was purchased from Shanghai Boyi Biotechnology Company (Shanghai, China). For systemic STC2 treatments, ob/ob mice received daily intraperitoneal (i.p.) injections of recombinant STC2 protein (0.5 mg/kg). Adenoviruses expressing murine STC2 gene or green fluorescent protein (GFP) (Ad-STC2 and Ad-GFP) were constructed by Genechem Company (Shanghai, China). Overexpression of STC2 or GFP in the liver of ob/ob mice was achieved by means of tail vein injection of Ad-STC2 or Ad-GFP [2 × 109 plaque-forming units (pfu) for each mouse]. All animal experiments were conducted in accordance with the guidelines of Animal Care Committee of Shanghai Jiao Tong University School of Medicine.

Cell Culture

Mouse primary hepatocytes (MPHs) were isolated from adult mice and maintained in hepatocyte medium (Sciencell, Carlsbad, CA, United States). HepG2 cells were cultured in DMEM (Gibco, Gaithersburg, MD, United States) containing 10% fetal bovine serum (FBS; Gibco), 100 IU/mL penicillin, and 100 μg/mL streptomycin. For the in vitro model of cellular steatosis, HepG2 cells were exposed to palmitic acid (PA) (200 μM) for 24 h to induce cellular TG accumulation, then were treated with recombinant STC2 protein (20 ng/mL) or vehicle control for another 24 h. To explore the potential signaling pathway affected by STC2, MPHs and HepG2 cells were starved in serum-free DMEM overnight and then treated with recombinant STC2 protein (20 ng/mL) for 1 h. To further investigate the role of STAT3 activation, HepG2 cells were pretreated with S31-201 (50 μM), a STAT3 inhibitor, to block STAT3 function, and then exposed to recombinant STC2 protein or vehicle control for 24 h. Cellular TG contents were extracted and determined using commercial kits (BioVision, Milpitas, CA, United States).

Biochemical Measurements

Plasma or hepatic TGs and plasma total cholesterol (TC) were extracted and quantified using commercial kits (BioVision), according to the manufacturer’s instructions.

Histological Analysis

For Hematoxylin and Eosin (H&E) staining, liver tissues were fixed overnight in 10% formalin, embedded in paraffin, and sectioned at 5 μm. Sections were subjected to standard H&E staining. For Oil Red O staining, liver tissues were fixed overnight in 4% paraformaldehyde, embedded in optimum cutting temperature compound, and cryosectioned. Frozen liver sections were stained with 0.15% Oil Red O according to standard procedures.

RNA Isolation and qRT-PCR

Total RNA was isolated from cell lysates or liver tissues using TRIzol® reagent according to the manufacturer’s instructions (Invitrogen, Shanghai, China). 2 μg of total RNA was reverse transcribed into cDNA using oligo-dT primers (Promega, Sunnyvale, CA, United States). Quantitative real-time PCR (qRT-PCR) was performed using SYBR® Green Premix Ex Taq (Takara, Shiga, Japan) on a Light Cycler 480 (Roche, Basel, Switzerland) to quantify the gene transcripts of interest. The 36B4 gene was used as an internal reference for normalization. The primer sequences are listed in the Table 1.

Table 1.

Description of primers used in real-time PCR.

Gene name Species Primer sequences (Forward 5′–3′) Primer sequences (Reverse 5′–3′)
36B4 Mouse AGATTCGGGATATGCTGTTGGC TCGGGTCCTAGACCAGTGTTC
STC2 Mouse CTGGGCCAGTTTGTGACCC ACGTCATGCAAATCCCATGTAAA
SREBP-1c Mouse CTTTGGCCTCGCTTTTCGG TGGGTCCAATTAGAGCCATCTC
FASN Mouse GGCTCTATGGATTACCCAAGC CCAGTGTTCGTTCCTCGGA
ACC1 Mouse AATGAACGTGCAATCCGATTTG ACTCCACATTTGCGTAATTGTTG
SCD1 Mouse TTCTTGCGATACACTCTGGTGC CGGGATTGAATGTTCTTGTCGT
PPARα Mouse AACATCGAGTGTCGAATATGTGG CCGAATAGTTCGCCGAAAGAA
CPT1α Mouse TGGCATCATCACTGGTGTGTT GTCTAGGGTCCGATTGATCTTTG
ACOX1 Mouse TAACTTCCTCACTCGAAGCCA AGTTCCATGACCCATCTCTGTC
MCAD Mouse AACACAACACTCGAAAGCGG TTCTGCTGTTCCGTCAACTCA
IL-6 Mouse AGTTGCCTTCTTGGGACTGA TCCACGATTTCCCAGAGAAC
TNF-α Mouse AGCCCCCAGTCTGTATCCTT CTCCCTTTGCAGAACTCAGG
MCP1 Mouse AGGTCCCTGTCATGCTTCTG TCTGGACCCATTCCTTCTTG
Nrf2 Mouse TCTTGGAGTAAGTCGAGAAGTGT GTTGAAACTGAGCGAAAAAGGC
HO1 Mouse AAGCCGAGAATGCTGAGTTCA GCCGTGTAGATATGGTACAAGGA
α-SMA Mouse GTCCCAGACATCAGGGAGTAA TCGGATACTTCAGCGTCAGGA
Col4a1 Mouse CTGGCACAAAAGGGACGAG ACGTGGCCGAGAATTTCACC
Col5a1 Mouse CTTCGCCGCTACTCCTGTTC CCCTGAGGGCAAATTGTGAAAA
Open in a new tab

Western Blots

Liver tissues and HepG2 cells were lysed in radioimmunoprecipitation (RIPA) buffer containing protease and phosphatase inhibitors (Millipore, Billerica, MA, United States). 50 μg lysates were loaded onto 10% SDS-PAGE and transferred to polyvinylidenedifluoride (PVDF) membranes (Millipore, United States), which were blocked with 10% Bovine Serum Albumin and immunoblotted with antibodies at 4°C overnight. The antibodies used in western blots included, STAT3 (#12640; 1:1000, #9145; 1:1000, Cell Signaling Technology, Danvers, MA, United States), AKT (#13038; 1:1000, #4821; 1:1000, Cell Signaling Technology), JNK (#4668; 1:1000, #9258;1:1000, Cell Signaling Technology), Stanniocalcin 2 (#A302-369A; 1:500, Bethyl Laboratories, Montgomery, TX, United States), and GAPDH (KC-5G5; 1:5000, Aksomics, Shanghai, China). The proteins were visualized with Immobilon Western Chemiluminescent HRP Substrate (Millipore, United States) according to the manufacturer’s protocol.

Insulin Tolerance Tests

ob/ob mice were injected i.p. with regular human insulin at a dose of 0.75 IU/kg body weight after fasting for 6 h. Blood glucose levels were monitored at the indicated time points using a portable blood glucose meter (LifeScan, Milpitas, CA, United States).

Statistical Analysis

All values are shown as the mean ± standard error of the mean (SEM). Statistical differences were determined by two-tailed Student’s t-tests. Statistical significances were shown as ∗P < 0.05, ∗∗P < 0.01, or ∗∗∗P < 0.001.

Results

Hepatic STC2 Expression Was Reduced in Obese Mice

To determine hepatic STC2 expression in obesity-associated NAFLD, we evaluated its mRNA and protein levels in the livers of ob/ob mice. Compared with lean mice, mRNA (Figure 1A) and protein (Figure 1B) levels of STC2 were significantly reduced in the livers of ob/ob mice. Similarly, the expression of hepatic STC2 was markedly decreased in mice fed a high fat diet (HFD) for 12 weeks as compared with mice fed a normal chow diet (NCD) (Figures 1C,D). These results indicated that downregulation of STC2 in the liver was a conserved feature of hepatosteatosis in obese mice.

FIGURE 1.

FIGURE 1

Open in a new tab

Hepatic STC2 expression was reduced in obese mice. (A,B) Hepatic Stanniocalcin 2 (STC2) mRNA and protein levels, determined by qRT-PCR and western blots, respectively, in ob/ob mice aged 8 weeks (n = 4–8). (C,D) Hepatic STC2 mRNA and protein levels, determined by qRT-PCR and western blots, respectively, in high fat diet (HFD) mice. The 8-week-old mice were fed normal chow diet (NCD) or a HFD for 12 weeks (n = 4–6). Data are expressed as the mean ± SEM. ∗∗∗P < 0.001.

STC2 Alleviated Cellular TG Accumulation Through Suppression of de Novo Lipogenesis

To investigate the role of STC2 in hepatic TG metabolism, HepG2 cells were treated with recombinant STC2 protein or vehicle control. As a result, we found that cellular TG contents were decreased upon STC2 treatment (Figure 2A). In addition, STC2 dramatically inhibited the palmitate-induced cellular TG deposition (Figure 2A). To explore the molecular basis for the anti-steatotic effect of STC2, expression levels of genes involved in hepatic TG homeostasis were determined by quantitative real-time PCR. SREBP-1c, a master regulator of de novo lipogenesis, was significantly downregulated by STC2 treatment (Figure 2B). In parallel, expression levels of its downstream target genes, including fatty acid synthetase (FASN), acetyl-CoA carboxylase (ACC1), and stearoyl-CoA desaturase-1 (SCD1), were also reduced (Figure 2B). However, fatty acid oxidation-related genes, including peroxisome proliferator-activated receptor α (PPARα), carnitine palmitoyl transferase 1α (CPT1α), medium-chain acyl-CoA dehydrogenase (MCAD), and acyl-CoA oxidase (ACOX1), were not altered by STC2 treatment (Figure 2C).

FIGURE 2.

FIGURE 2

Open in a new tab

STC2 alleviated hepatic TG accumulation through suppression of de novo lipogenesis. (A) Cellular triglyceride (TG) contents in HepG2 cells. Cells were treated with recombinant STC2 protein (20 ng/mL) or phosphate-buffered saline (PBS) as a vehicle control for 24 h, with or without preincubated with palmitic acid (PA; 200 μM) for 24 h. (B) The mRNA levels of SREBP-1c, FASN, ACC1, and SCD1 in HepG2 cells were measured. Cells were exposed to PA (200 μM) for 24 h, then were treated with recombinant STC2 protein (20 ng/mL) or vehicle control (PBS) for another 24 h. (C) The mRNA levels of PPARα, ACOX1, MCAD, and CPT1α in HepG2 were measured as in (B). Data are expressed as the mean ± SEM. ∗∗P < 0.01, ∗∗∗P < 0.001.

STC2 Activated the STAT3 Signaling Pathway to Alleviate Hepatosteatosis

We analyzed the potential mechanism by which STC2 suppressed lipogenesis and alleviated TG accumulation in hepatocytes. We found that STC2 treatment resulted in marked activation of the STAT3 signaling pathway, as shown by enhanced phosphorylated STAT3, while the AKT and JNK pathways were unaffected (Figures 3A,B). To determine whether STAT3 activation was indispensable for the anti-steatotic effects of STC2, S31-201, a STAT3 inhibitor, was used to block STAT3 function. Our data showed that S31-201 abrogated the effects of STC2 on TG contents and lipogenic gene expression (Figures 3C,D).

FIGURE 3.

FIGURE 3

Open in a new tab

STC2 activated the STAT3 signaling pathway to alleviate hepatosteatosis. (A,B) Phosphorylated and total STAT3, AKT, and JNK in HepG2 cells (A) and MPHs (B) incubated with PBS or STC2 (20 ng/mL) protein for 1 h. Total STAT3, AKT, and JNK were used as loading controls. (C) Cellular TG contents in HepG2. Cells were treated with recombinant STC2 protein (20 ng/mL) or PBS vehicle control for 24 h, with or without preincubation with S31-201 (50 μM), a STAT3 inhibitor, for 2 h. (D) The mRNA levels of SREBP-1c and its target genes in HepG2 cells were measured as in (C). Data are expressed as the mean ± SEM. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.

Systemic STC2 Treatment Ameliorated Hepatosteatosis in Obese Mice

To elucidate the function of STC2 in vivo, ob/ob mice were injected i.p. with recombinant STC2 protein (0.5 mg/kg) once daily. A drastic decrease in hepatic TG contents (Figure 4A) and liver weight (Figure 4B) were observed in STC2-treated mice. Systemic STC2 administration also decreased the balloon cells and neutral lipid deposition in the livers of ob/ob mice as assessed by H&E and Oil Red O staining (Figure 4C). Plasma TG and total cholesterol (TC) levels were markedly reduced (Figures 4D,E). In parallel, STC2 partially ameliorated the inflammation, oxidative stress and fibrosis characteristics of ob/ob mice (Supplementary Figures S1A–C). Plasma ALT and AST levels were also significantly decreased in STC2-treated mice (Supplementary Figures S1D,E). In addition, fasting blood glucose levels and insulin sensitivity were dramatically improved upon STC2 treatment (Figures 4F,G). Consistently, STC2 also activated the STAT3 pathway and reduced the expression of SREBP-1c and its target genes in the liver (Figures 4H,I).

FIGURE 4.

FIGURE 4

Open in a new tab

Systemic STC2 treatment ameliorated hepatosteatosis in obese mice. (A,B) Liver TG contents (A) and liver weight (B) in ob/ob mice intraperitoneally injected with recombinant STC2 protein (0.5 mg/kg) or vehicle control for 9 days (n = 7–8). (C) Representative histology (H&E, left) or Oil Red O (right) staining showing TG accumulation in livers from mice injected with STC2 protein versus vehicle control. Original magnification, 200×. (D,E) Plasm TG (D) and plasm TC (E) levels in mice. (F,G) Fasting blood glucose (F) and insulin tolerance test results (G) in mice. (H) Phosphorylated and total STAT3 in the livers of mice. Total STAT3 were used as loading controls. (I) The mRNA levels of hepatic SREBP-1c and its target genes in mice. Data are expressed as the mean ± SEM. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001. H&E, Hematoxylin & Eosin; TG, triglyceride; TC, total cholesterol.

Hepatic STC2 Overexpression Attenuated Fatty Livers in ob/ob Mice

Next, STC2 gene was overexpressed in the livers of ob/ob mice by delivering an adenovirus via tail vein injection. Increased mRNA and protein levels of STC2 in the liver were confirmed by qRT-PCR and western blots, respectively, while its expression in white adipose tissues were not affected (Figure 5A and Supplementary Figures S2A,B). Hepatic overexpression of STC2 significantly decreased liver TG content (Figure 5B) and liver weight (Figure 5C). Plasma TG levels were markedly reduced (Figure 5D), and a declining tendency in plasma TC levels was also observed (Figure 5E). Consistently, hepatic overexpression of STC2 partially ameliorated the inflammation, oxidative stress and fibrosis characteristics of ob/ob mice (Supplementary Figures S2C–E). Plasma ALT levels were significantly reduced, while AST levels were not affected in STC2-overexpressed ob/ob mice (Supplementary Figures S2F,G). In addition, fasting hyperglycemia and insulin resistance were improved by STC2 overexpression in ob/ob mice (Figures 5F,G). At the molecular level, overexpression of STC2 also induced hepatic STAT3 activation and reduced the expression of de novo lipogenesis related genes (Figures 5H,I).

FIGURE 5.

FIGURE 5

Open in a new tab

Hepatic STC2 overexpression attenuated fatty liver in ob/ob mice. (A) The mRNA and protein levels of STC2 in ob/ob mice injected with adenovirus containing GFP or the STC2 gene (n = 7–8). (B,C) Liver TG contents (B) and liver weights (C) in mice. (D,E) Plasm TG (D) and plasm TC (E) levels in mice. (F,G) Fasting blood glucose (F) and insulin tolerance test results (G) in mice. (H) Phosphorylated and total STAT3 in the livers of mice. Total STAT3 were used as loading controls. (I) The mRNA expressions of hepatic SREBP-1c and its target genes in mice. Data are expressed as the mean ± SEM. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001. TG, triglyceride; TC, total cholesterol.

Discussion

Previous studies have shown that STC2 regulates many biological processes, including tissue remodeling, cell survival, stress responses, and tumorigenesis. However, little is known about its function in metabolic homeostasis. Interestingly, STC2 knockout mice were reported to present with deregulated glycemia when they were fed with a hypercaloric diet (López et al., 2017). Enhanced glucagon immunostaining in the islet cells and elevated circulating glucagon levels were observed in STC2-null mice (López et al., 2017).

In the present study, we identified a novel role of STC2 in the regulation of hepatic TG homeostasis. Systemic STC2 administration or liver-specific overexpression of STC2 significantly ameliorated TG accumulation in obese mice. At the molecular level, it has been shown that STC2 can modulate multiple signaling pathways, such as PI3K/AKT, ERK1/2, in tumor cells and osteoblast (Zhou et al., 2016; Yang et al., 2017). However, our data showed that the AKT and JNK pathways were unaffected in STC2-treated hepatocytes. Therefore, the role and downstream signaling pathways of STC2 might be tissue or cell-specific, which needs further investigations in future studies.

In addition, studies using genetically engineered mice have shown the significance of the STAT3 signaling pathway in the pathophysiology of fatty liver. The anti-steatotic effects of STAT3 were mediated, at least in part, via transcriptional suppression of SREBP-1c and subsequent repression of hepatic de novo lipogenesis (Ueki et al., 2004). As a result, disruption of STAT3 or its upstream molecule gp130 in hepatocytes exacerbated fatty liver induced by a high fat diet (Inoue et al., 2004), alcohol-containing diet (Horiguchi et al., 2008), or a choline deficient ethionine-supplemented diet (Kroy et al., 2010). Overexpression of constitutively activated STAT3 attenuated high fat diet-induced fatty livers (Inoue et al., 2004). Consistently, genetic variants in STAT3 were associated with non-alcoholic fatty liver disease in humans (Sookoian et al., 2008). Furthermore, several cytokines are known to activate the STAT3 pathway to regulate hepatic TG homeostasis. For instance, treatment with IL-6 ameliorated fatty liver by inducing STAT3 phosphorylation in ob/ob and HFD- induced obese mice (Hong et al., 2004), while deletion of IL-6 or hepatic STAT3 resulted in steatosis and hepatocellular damage in IL-10 knockout mice (Miller et al., 2011). In addition, IL-22 ameliorated non-alcoholic and alcoholic fatty livers through activation of the STAT3 pathway in hepatocytes (Ki et al., 2010; Yang et al., 2010). Here, in our studies we found that plasma IL-22 contents were reduced by STC2 treatment or overexpression (Supplementary Figures S3A,B). Previous studies have shown that inflammatory signaling, including NF-κB and AP-1/JunD, are involved in IL-22 production (Ouyang et al., 2011; Ahlfors et al., 2014; Fumagalli et al., 2016). Since STC2 treatment can reduce hepatic inflammation in obese mice, we speculate that reduction of IL-22 in STC-2 treated mice might be attributed to decreased inflammation.

Conclusion

Our findings demonstrated that STC2 was an important metabolic regulator in the liver. STC2 ameliorated hepatosteatosis and hypertriglyceridemia in obese mice, mainly through activation of the STAT3 signaling pathway. Thus, STC2 may be a promising therapeutic target for fatty liver and dyslipidemia.

Author Contributions

YL, JY, HZ, and XL conceived the project. YL, JZ, and YJ designed the experiments. JZ, YJ, and YS performed the experiments and statistical analysis. JZ, YJ, and YL drafted the manuscript. YJ, YL, JL, and XL handled funding and supervision. All authors reviewed the manuscript.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer DV and handling Editor declared their shared affiliation.

Footnotes

Funding. This study was supported by grants from National Natural Science Foundation of China (Nos. 81570769 and 81570785), Science and Technology Commission of Shanghai Municipality (18dz2304400 and 15411970700), Chenguang Program supported by Shanghai Education Development Foundation, Shanghai Municipal Education Commission (15CG11), and the Doctoral Innovation Fund Projects from Shanghai Jiao Tong University School of Medicine (BXJ201708).

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphys.2018.00873/full#supplementary-material

FIGURE S1

Systemic STC2 treatment ameliorated hepatosteatosis in obese mice. (A) Relative mRNA levels of IL-6, TNF-α, MCP1 in the livers of two groups. (B) Relative mRNA levels of Nrf2, HO1 in the livers of two groups. (C) Relative mRNA levels of hepatic α-SMA, Col4a1, Col5a1in two groups. (D,E) Plasma ALT and AST levels in two groups. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001. MCP1, Chemokine (C-C motif) ligand 2 (CCL2); Nrf2, nuclear factor, erythroid derived 2, like 2; HO1, heme oxygenase 1; Col4a1, collagen, type IV, alpha 1; Col5a1, collagen, type V, alpha 1.

Click here for additional data file. (256KB, TIF)
FIGURE S2

Hepatic STC2 overexpression attenuated fatty liver in ob/ob mice. (A,B) Relative mRNA and protein expression of STC2 in white adipose tissues. (C) Relative mRNA levels of IL-6, TNF-α, MCP1 in the livers of two groups. (D) Relative mRNA levels of Nrf2, HO1 in the livers of two groups. (E) Relative mRNA levels of hepatic α-SMA, Col4a1, Col5a1 in two groups. (F,G) Plasma ALT and AST levels in two groups. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.

Click here for additional data file. (518.7KB, TIF)
FIGURE S3

Plasma IL-22 contents in systemic STC2-treated and hepatic STC2 overexpressed ob/ob mice. (A,B) Plasma IL-22 contents in STC2-treated ob/ob mice (A) or hepatic STC2 overexpressed ob/ob mice (B) by ELISA kit. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.

Click here for additional data file. (146.3KB, TIF)

References

  1. Ahlfors H., Morrison P. J., Duarte J. H., Li Y., Biro J., Tolaini M., et al. (2014). IL-22 fate reporter reveals origin and control of IL-22 production in homeostasis and infection. J. Immunol. 193 4602–4613. 10.4049/jimmunol.1401244 [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Arigami T., Uenosono Y., Ishigami S., Yanagita S., Hagihara T., Haraguchi N., et al. (2013). Clinical significance of stanniocalcin 2 expression as a predictor of tumor progression in gastric cancer. Oncol. Rep. 30 2838–2844. 10.3892/or.2013.2775 [DOI] [PubMed] [Google Scholar]
  3. Browning J. D., Szczepaniak L. S., Dobbins R., Nuremberg P., Horton J. D., Cohen J. C., et al. (2004). Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40 1387–1395. 10.1002/hep.20466 [DOI] [PubMed] [Google Scholar]
  4. Chen B., Zeng X., He Y., Wang X., Liang Z., Liu J., et al. (2016). STC2 promotes the epithelial mesenchymal transition of colorectal cancer cells through AKT-ERK signaling pathways. Oncotarget 7 71400–71416. 10.18632/oncotarget.12147 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cohen J. C., Horton J. D., Hobbs H. H. (2011). Human fatty liver disease: old questions and new insights. Science 332 1519–1523. 10.1126/science.1204265 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Farrell G. C., Larter C. Z. (2006). Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43 S99–S112. 10.1002/hep.20973 [DOI] [PubMed] [Google Scholar]
  7. Fumagalli S., Torri A., Papagna A., Citterio S., Mainoldi F., Foti M. (2016). IL-22 is rapidly induced by Pathogen Recognition Receptors Stimulation in Bone-Marrow-derived Dendritic Cells in the Absence of IL-23. Sci. Rep. 6:33900. 10.1038/srep33900 [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hong F., Radaeva S., Pan H. N., Tian Z., Veech R., Gao B. (2004). Interleukin 6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease. Hepatology 40 933–941. 10.1002/hep.20400 [DOI] [PubMed] [Google Scholar]
  9. Horiguchi N., Wang L., Mukhopadhyay P., Park O., Jeong W. I., Lafdil F., et al. (2008). Cell type-dependent pro- and anti-inflammatory role of signal transducer and activator of transcription 3 in alcoholic liver injury. Gastroenterology 134 1148–1158. 10.1053/j.gastro.2008.01.016 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Horton J. D., Goldstein J. L., Brown M. S. (2002). SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109 1125–1131. 10.1172/JCI0215593 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Inoue H., Ogawa W., Ozaki M., Haga S., Matsumoto M., Furukawa K., et al. (2004). Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat. Med. 10 168–174. 10.1038/nm980 [DOI] [PubMed] [Google Scholar]
  12. Jepsen M. R., Kløverpris S., Bøtkjær J. A., Wissing M. L., Andersen C. Y., Oxvig C. (2016). The proteolytic activity of pregnancy-associated plasma protein-A is potentially regulated by stanniocalcin-1 and -2 during human ovarian follicle development. Hum. Reprod. 31 866–874. 10.1093/humrep/dew013 [DOI] [PubMed] [Google Scholar]
  13. Ki S. H., Park O., Zheng M., Morales-Ibanez O., Kolls J. K., Bataller R., et al. (2010). Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3. Hepatology 52 1291–1300. 10.1002/hep.23837 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kroy D. C., Beraza N., Tschaharganeh D. F., Sander L. E., Erschfeld S., Giebeler A., et al. (2010). Lack of interleukin-6/glycoprotein 130/signal transducers and activators of transcription-3 signaling in hepatocytes predisposes to liver steatosis and injury in mice. Hepatology 51 463–473. 10.1002/hep.23322 [DOI] [PubMed] [Google Scholar]
  15. Lambert J. E., Ramos-Roman M. A., Browning J. D., Parks E. J. (2014). Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 146 726–735. 10.1053/j.gastro.2013.11.049 [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Law A. Y., Wong C. K. (2010). Stanniocalcin-2 is a HIF-1 target gene that promotes cell proliferation in hypoxia. Exp. Cell Res. 316 466–476. 10.1016/j.yexcr.2009.09.018 [DOI] [PubMed] [Google Scholar]
  17. López J. J., Jardín I., Cantonero Chamorro C., Duran M. L., Tarancón Rubio M. J., Reyes Panadero M., et al. (2017). Involvement of stanniocalcins in the deregulation of glycaemia in obese mice and type 2 diabetic patients. J. Cell. Mol. Med. 22 684–694. 10.1111/jcmm.13355 [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Marignani M., Angeletti S. (2002). Nonalcoholic fatty liver disease. N. Engl. J. Med. 346 1221–1231. 10.1056/NEJMra011775 [DOI] [PubMed] [Google Scholar]
  19. Meyer H. A., Tölle A., Jung M., Fritzsche F. R., Haendler B., Kristiansen I., et al. (2009). Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma. Eur. Urol. 55 669–678. 10.1016/j.eururo.2008.04.001 [DOI] [PubMed] [Google Scholar]
  20. Miller A. M., Wang H., Bertola A., Park O., Horiguchi N., Ki S. H., et al. (2011). Inflammation-associated interleukin-6/signal transducer and activator of transcription 3 activation ameliorates alcoholic and nonalcoholic fatty liver diseases in interleukin-10-deficient mice. Hepatology 54 846–856. 10.1002/hep.24517 [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Ouyang W., Rutz S., Crellin N. K., Valdez P. A., Hymowitz S. G. (2011). Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu. Rev. Immunol. 29 71–109. 10.1146/annurev-immunol-031210-101312 [DOI] [PubMed] [Google Scholar]
  22. Shimomura I., Bashmakov Y., Horton J. D. (1999). Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J. Biol. Chem. 274 30028–30032. 10.1074/jbc.274.42.30028 [DOI] [PubMed] [Google Scholar]
  23. Sookoian S., Castano G., Gianotti T. F., Gemma C., Rosselli M. S., Pirola C. J. (2008). Genetic variants in STAT3 are associated with nonalcoholic fatty liver disease. Cytokine 44 201–206. 10.1016/j.cyto.2008.08.001 [DOI] [PubMed] [Google Scholar]
  24. Ueki K., Kondo T., Tseng Y. H., Kahn C. R. (2004). Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc. Natl. Acad. Sci. U.S.A. 101 10422–10427. 10.1073/pnas.0402511101 [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Wagner G. F., Hampong M., Park C. M., Copp D. H. (1986). Purification, characterization, and bioassay of teleocalcin, a glycoprotein from salmon corpuscles of Stannius. Gen. Comp. Endocrinol. 63 481–491. 10.1016/0016-6480(86)90149-8 [DOI] [PubMed] [Google Scholar]
  26. Williams C. D., Stengel J., Asike M. I., Torres D. M., Shaw J., Contreras M., et al. (2011). Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140 124–131. 10.1053/j.gastro.2010.09.038 [DOI] [PubMed] [Google Scholar]
  27. Wong V. W., Chu W. C., Wong G. L., Chan R. S., Chim A. M., Ong A., et al. (2012). Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 61 409–415. 10.1136/gutjnl-2011-300342 [DOI] [PubMed] [Google Scholar]
  28. Wu F., Li T. Y., Su S. C., Yu J. S., Zhang H. L., Tan G. Q., et al. (2017). STC2 as a novel mediator for Mus81-dependent proliferation and survival in hepatocellular carcinoma. Cancer Lett. 388 177–186. 10.1016/j.canlet.2016.11.039 [DOI] [PubMed] [Google Scholar]
  29. Yang L., Zhang Y., Wang L., Fan F., Zhu L., Li Z., et al. (2010). Amelioration of high fat diet induced liver lipogenesis and hepatic steatosis by interleukin-22. J. Hepatol. 53 339–347. 10.1016/j.jhep.2010.03.004 [DOI] [PubMed] [Google Scholar]
  30. Yang S., Ji Q., Chang B., Wang Y., Zhu Y., Li D., et al. (2017). STC2 promotes head and neck squamous cell carcinoma metastasis through modulating the PI3K/AKT/Snail signaling. Oncotarget 8 5976–5991. 10.18632/oncotarget.13355 [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Zhou J., Li Y., Yang L., Wu Y., Zhou Y., Cui Y., et al. (2016). Stanniocalcin 2 improved osteoblast differentiation via phosphorylation of ERK. Mol. Med. Rep. 14 5653–5659. 10.3892/mmr.2016.5951 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

FIGURE S1

Systemic STC2 treatment ameliorated hepatosteatosis in obese mice. (A) Relative mRNA levels of IL-6, TNF-α, MCP1 in the livers of two groups. (B) Relative mRNA levels of Nrf2, HO1 in the livers of two groups. (C) Relative mRNA levels of hepatic α-SMA, Col4a1, Col5a1in two groups. (D,E) Plasma ALT and AST levels in two groups. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001. MCP1, Chemokine (C-C motif) ligand 2 (CCL2); Nrf2, nuclear factor, erythroid derived 2, like 2; HO1, heme oxygenase 1; Col4a1, collagen, type IV, alpha 1; Col5a1, collagen, type V, alpha 1.

Click here for additional data file. (256KB, TIF)
FIGURE S2

Hepatic STC2 overexpression attenuated fatty liver in ob/ob mice. (A,B) Relative mRNA and protein expression of STC2 in white adipose tissues. (C) Relative mRNA levels of IL-6, TNF-α, MCP1 in the livers of two groups. (D) Relative mRNA levels of Nrf2, HO1 in the livers of two groups. (E) Relative mRNA levels of hepatic α-SMA, Col4a1, Col5a1 in two groups. (F,G) Plasma ALT and AST levels in two groups. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.

Click here for additional data file. (518.7KB, TIF)
FIGURE S3

Plasma IL-22 contents in systemic STC2-treated and hepatic STC2 overexpressed ob/ob mice. (A,B) Plasma IL-22 contents in STC2-treated ob/ob mice (A) or hepatic STC2 overexpressed ob/ob mice (B) by ELISA kit. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.

Click here for additional data file. (146.3KB, TIF)

Articles from Frontiers in Physiology are provided here courtesy of Frontiers Media SA

RESOURCES